Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Expands By 125.7%

Assembly Biosciences, Inc. (NASDAQ:ASMBGet Free Report) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 453,600 shares, an increase of 125.7% from the December 31st total of 201,000 shares. Based on an average trading volume of 627,400 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Assembly Biosciences in a research note on Tuesday, October 24th. They issued a “hold” rating on the stock.

View Our Latest Research Report on ASMB

Insider Buying and Selling at Assembly Biosciences

In other news, major shareholder Alexander Schornstein bought 299,994 shares of the stock in a transaction on Wednesday, January 17th. The stock was bought at an average cost of $0.78 per share, for a total transaction of $233,995.32. Following the completion of the purchase, the insider now directly owns 7,864,286 shares in the company, valued at $6,134,143.08. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in shares of Assembly Biosciences in the first quarter worth approximately $27,000. Tower Research Capital LLC TRC boosted its position in shares of Assembly Biosciences by 110.2% in the third quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 8,992 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Assembly Biosciences by 15,633.0% in the first quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 14,695 shares during the period. UBS Group AG lifted its position in Assembly Biosciences by 110.0% in the fourth quarter. UBS Group AG now owns 24,007 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 12,576 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Assembly Biosciences during the first quarter valued at $32,000. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Stock Performance

Shares of NASDAQ ASMB traded down $0.01 during midday trading on Friday, reaching $0.90. 148,185 shares of the stock were exchanged, compared to its average volume of 330,988. Assembly Biosciences has a 52-week low of $0.64 and a 52-week high of $1.78. The stock has a 50 day moving average price of $0.78 and a 200-day moving average price of $0.88.

Assembly Biosciences (NASDAQ:ASMBGet Free Report) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). On average, equities analysts anticipate that Assembly Biosciences will post -1.19 earnings per share for the current year.

About Assembly Biosciences

(Get Free Report)

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.

Further Reading

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.